Development of a highly productive and scalable plasmid DNA production platform

Area of Science:

• Biotechnology
• Molecular Biology
• Vaccine Development

Background:

• Clinical-grade plasmid DNA production is crucial for DNA vaccine success.
• First-generation processes using Escherichia coli achieved moderate yields but faced variability issues due to monosodium glutamate (MSG).

Purpose of the Study:

• To develop a second-generation, MSG-free plasmid DNA production process.
• To optimize cultivation conditions for enhanced plasmid DNA yield and reproducibility.
• To demonstrate the scalability and robustness of the new process for clinical supplies.

Main Methods:

• Utilized a chemically defined medium and feed solution excluding MSG.
• Employed fed-batch cultivation of Escherichia coli engineered to produce a plasmid encoding the HIV gag protein.
• Conducted optimization studies and scaled up the process in 2,000-L bioreactors.

Main Results:

• Achieved volumetric plasmid DNA titers exceeding 1.2 g/L, a significant improvement over the first-generation process.
• Obtained specific yields of 25-32 µg plasmid DNA/mg dry cell weight.
• Demonstrated process applicability to multiple plasmid constructs upon scale-up.

Conclusions:

• The second-generation, MSG-free process is highly productive, scalable, and robust.
• This optimized process overcomes limitations of previous methods, enabling more efficient DNA vaccine manufacturing.
• The developed method is suitable for producing clinical-grade plasmid DNA for diverse vaccine applications.